NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00088218,Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).,https://clinicaltrials.gov/study/NCT00088218,,COMPLETED,The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in patients who are 60 years or older. The safety of these treatments will also be compared.,YES,Acute Myeloid Leukemia|Myelodysplastic Syndrome,DRUG: Clofarabine|DRUG: Ara-C,"Number of Participants With Response, Participant responses are categorized as 'Complete Remission,' Complete Remission, No Platelet Recovery,' 'No Response.'

Complete Remission: Disappearance of all clinical and/or radiologic evidence of disease. Neutrophil count \> 1.0 x 109/L and platelet count \> 100 x 109/L, and normal bone marrow differential (\< 5% blasts); Complete Remission, No Platelet Recovery: Peripheral blood and bone marrow results as for CR, but with platelet counts of \< 100 x 109/L.

Blood draws once a week until remission then every 2 to 8 weeks during therapy., Every 2 to 8 weeks",,,M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",ALL,"ADULT, OLDER_ADULT",PHASE2,95,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2004-0183,2004-07,2008-02,2008-02,2004-07-23,2011-05-09,2012-08-07,"M.D. Anderson Cancer Center, Houston, Texas, 77030, United States",
